June 15, 2016 (Shareholders Foundation) - An investigation on behalf of investors of ProNAi Therapeutics Inc (NASDAQ:DNAI) shares over potential securities laws violations by ProNAi Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of ProNAi Therapeutics Inc (NASDAQ:DNAI) concerning whether a series of statements by ProNAi Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 6, 2016, ProNAi Therapeutics Inc (NASDAQ:DNAI announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). ProNAi Therapeutics Incs President and CEO Nick Glover said, Although [PNT2258] observed modest efficacy in [the] interim analysis of Wolverine, the Company has decided to suspend the development of PNT2258 because the results were not robust enough to justify continued development of the drug in DLBCL.

Shares of ProNAi Therapeutics Inc (NASDAQ:DNAI) declined from $6.70 per share on June 2, 2016, to $1.98 per share on June 10, 2016.